4DMT reports 78% treatment-burden reduction in 2-year wet AMD Phase 2b data

The company said a single intravitreal dose of 4D-150 maintained visual acuity and retinal anatomy, while the recently diagnosed subgroup showed an 87% reduction versus projected aflibercept dosing.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.